Cardiometabolic Disease Staging and Major Adverse Cardiovascular Event Prediction in 2 Prospective Cohorts
Authors' conclusion
The CMDS predicted the onset of MACE with good predictive ability and performed similarly or better than 2 commonly known cardiovascular disease prediction risk tools.
Study context
- Population
- REGARDS participants with no history of stroke or MI (mean age 64 ± 9.3 years, 58% female, 41% non-Hispanic Black, 18% DM)REGARDS
- Participants
- 20,234 participants
- Comparison
- Cardiometabolic disease staging (CMDS) vs ACC/AHA 10-year risk estimate vs Framingham risk score for major adverse cardiovascular events (MACE) prediction
- Outcome
- MACE:
- CV death
- Nonfatal MI
- Nonfatal stroke
- Follow-up
- median 10-year follow-up
Performance
As reported in the abstract
Prediction of MACE (AUC)
| Test or model | AUC |
|---|---|
| CMDS | 0.721 |
| ACC/AHA 10-year risk estimate | 0.716 |
| Framingham risk score | 0.673 |
AUC
CMDS0.721
ACC/AHA 10-year risk estimate0.716
Framingham risk score0.673
Further findings
Incident MACE · median 10-year follow-up
- Participants developing incident MACE
- 2,695 (13.3%)
Original publication
Cardiometabolic Disease Staging and Major Adverse Cardiovascular Event Prediction in 2 Prospective Cohorts. JACC Adv. Published 17 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →